Brief: Intelgenx Announces Enrollment Reaches Halfway Mark In ‘Buena’ Montelukast Versafilm® Phase 2A Clinical Trial In Patients With Mild To Moderate Alzheimer’S Disease
08/09/2022 13:08
Sept 8 (Reuters) - Intelgenx Technologies Corp IGX.TO :
* INTELGENX ANNOUNCES ENROLLMENT REACHES HALFWAY MARK IN
‘BUENA’
MONTELUKAST VERSAFILM® PHASE 2A CLINICAL TRIAL IN PATIENTS WITH
MILD TO MODERATE ALZHEIMER’S DISEASE
* INTELGENX TECHNOLOGIES CORP - ANTICIPATE COMPLETING
ENROLLMENT
BEFORE END OF 2022
Source text for Eikon: ID:nGNX8mjzP2
Further company coverage: IGX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA